Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674581 · ClinicalTrials.gov registry record · Phase 1
A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02674581 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 30 participants.
The verdict
NCT02674581, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.
Interventions
- DRUG Oral BMS-663068 (pro-drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-02-26 |
| Est. Completion | 2016-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02674581
The ClinicalTrials.gov registry entry for NCT02674581 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral BMS-663068 (pro-drug) is the first listed.
NCT02674581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02674581 about?
NCT02674581 is a clinical study titled "A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)". An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.
What is the current status of trial NCT02674581?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-02-26. Estimated completion is 2016-05-24.
What interventions are being tested in trial NCT02674581?
The interventions under investigation include: Oral BMS-663068 (pro-drug) (DRUG).
Who is sponsoring clinical trial NCT02674581?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.